Multiple myeloma cancer stem cells

Carol Ann Huff, William Matsui

Research output: Contribution to journalReview articlepeer-review

Abstract

Multiple myeloma is characterized by the clonal expansion of neoplastic plasma cells within the bone marrow, elevated serum immunoglobulin, and osteolytic bone disease. The disease is highly responsive to a wide variety of anticancer treatments including conventional cytotoxic chemotherapy, corticosteroids, radiation therapy, and a growing number of agents with novel mechanisms of action. However, few if any patients are cured with these modalities and relapse remains a critical issue. A better understanding of clonogenic multiple myleoma cells is essential to ultimately improving long-term outcomes, but the nature of the cells responsible for myeloma regrowth and disease relapse is unclear. We review evidence that functional heterogeneity exists in multiple myeloma and discuss potential strategies and clinical implications of the stem-cell model of cancer in this disease.

Original languageEnglish (US)
Pages (from-to)2895-2900
Number of pages6
JournalJournal of Clinical Oncology
Volume26
Issue number17
DOIs
StatePublished - 2008

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Multiple myeloma cancer stem cells'. Together they form a unique fingerprint.

Cite this